Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis
D Vyas, G Laput, AK Vyas - OncoTargets and therapy, 2014 - Taylor & Francis
D Vyas, G Laput, AK Vyas
OncoTargets and therapy, 2014•Taylor & FrancisThe lack of therapy and the failure of existing therapy has been a challenge for clinicians in
treating various cancers. Doxorubicin, 5-fluorouracil, cisplatin, and paclitaxel are the first-line
therapy in various cancers; however, toxicity, resistance, and treatment failure limit their
clinical use. Their status leads us to discover and investigate more targeted therapy with
more efficacy. In this article, we dissect literature from the patient perspective, the tumor
biology perspective, therapy-induced metastasis, and cell data generated in the laboratory.
treating various cancers. Doxorubicin, 5-fluorouracil, cisplatin, and paclitaxel are the first-line
therapy in various cancers; however, toxicity, resistance, and treatment failure limit their
clinical use. Their status leads us to discover and investigate more targeted therapy with
more efficacy. In this article, we dissect literature from the patient perspective, the tumor
biology perspective, therapy-induced metastasis, and cell data generated in the laboratory.
The lack of therapy and the failure of existing therapy has been a challenge for clinicians in treating various cancers. Doxorubicin, 5-fluorouracil, cisplatin, and paclitaxel are the first-line therapy in various cancers; however, toxicity, resistance, and treatment failure limit their clinical use. Their status leads us to discover and investigate more targeted therapy with more efficacy. In this article, we dissect literature from the patient perspective, the tumor biology perspective, therapy-induced metastasis, and cell data generated in the laboratory.
Taylor & Francis Online